Developing Story: The Camizestrant Vote, Doctors Weigh In with Dr. Sarah Sammons & Dr. Neil Vasan
When the ODAC voted 6–3 against the camizestrant strategy, the headlines told you what happened — this episode tells you why. We're back for round two with Dr. Sarah Sammons, newly appointed Co-Leader of Breast Oncology at the University of Maryland Greenebaum Comprehensive Cancer Center, and Dr. Neil Vasan, Acting Chair of the ODAC and Director of Translational Research in Breast Cancer at NYU Langone Health, who sat in that room and cast one of the three yes votes. Alongside patient advocates Janice Cowden and Abigail Johnston, we break down the four FDA critiques that drove the vote, what the quality of life data showed and why regulators couldn't act on it, and what the FDA's new August 14th review deadline means for patients. Plus: why this science isn't going anywhere, and what ctDNA-guided treatment could look like in the very near future.
Developing Story: The Camizestrant Vote — When Your Blood Test Knows Before Your Scan Does
Six MBC patient advocates join host Victoria Goldberg to break down the FDA advisory committee's vote on camizestrant and the SERENA-6 trial. The panel unpacks what the vote really means, whether the science of molecular progression is ready for clinical practice, and why patient advocates need a seat at the table before trials are designed.
Front Row Seat: Dr. Fatima Cardoso on Aiming Higher - Hope and the Road to a Cure
For decades, metastatic breast cancer meant one thing: managing the disease. But a new global report — and a bold new charter — say it's time to aim higher. Host Victoria Goldberg sits down with Dr. Fátima Cardoso of the ABC Global Alliance to examine 10 years of hard-won progress, confront the inequalities that have grown worse, and explore why, for the first time, the word cure is entering the conversation.
Front Row Seat: We'll Never Cure Cancer Without AI, Say Steve Brown & Lisa Booth
When Steve Brown's doctors missed his rare blood cancer for months, he turned to AI for answers. The system he built spotted the warning signs immediately—the same lab results his physicians had dismissed.
Now, as CEO of CureWise, Steve and patient advocate Lisa Booth are pioneering a new approach to cancer care: using AI agents trained as specialist doctors to help patients navigate treatment options, find clinical trials, and advocate effectively with their oncologists.
"There's a gap between what's possible and what most people are getting," Steve explains. "Cancer isn't just one disease. Everybody has their own unique version of it."
Lisa, an 11-year metastatic breast cancer survivor, adds: "My oncologist sees 600 patients. CureWise empowers me to show up to that seven-minute appointment with the right questions already researched and the clinical trials already identified."
This conversation explores how AI is transforming patient empowerment—and why knowledge might just save your life.
Live Chat: The Courage to Choose Life on Your Terms with Dar Finkelstein
"One of my MBC friends said to me, 'You're feeling guilty about making people cry, but you've instilled in them so much joy and what they're doing, what you're seeing is them sharing the joy back to you.' And she said, 'It looks like tears, but that's their love coming back to you.'"
—Dar Finkelstein on accepting loved ones' grief